Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05265546 · ClinicalTrials.gov registry record · Phase 1
Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain
A Phase 1 study of Perception Disorders, sponsored by University of California, Berkeley.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05265546: Recruiting Phase 1 study of Perception Disorders, sponsored by University of California, Berkeley.
NCT05265546 is a Phase 1 study of Perception Disorders that is actively recruiting participants, run by University of California, Berkeley. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05265546, a Phase 1 study of Perception Disorders, is actively recruiting participants, sponsored by University of California, Berkeley.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The long-term objective of this project is to characterize how psilocybin affects visual perception and the brain's representation of the visual environment. It is known that psilocybin alters aspects of visual perception, but the underlying brain mechanisms contributing to these effects are poorly understood. The proposed work will address these questions in a large, diverse sample of healthy human subjects by using functional magnetic resonance imaging (fMRI) to measure the brain's responses to visual stimuli. The proposed research will document which brain areas mediate the effects of psilocybin. The technique of fMRI will be employed to measure brain activity in different brain areas while subjects are performing a visual perceptual task.
Primary Outcome
Functional magnetic resonance imaging (fMRI) responses to visual stimuli will be recorded.
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
California
- University of California, Berkeley - Berkeley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-03-08 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
What NCT05265546 shows while recruiting
NCT05265546 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).
The record links to 1 condition, with Perception Disorders appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT05265546 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05265546 about?
NCT05265546 is a clinical study titled "Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain". The long-term objective of this project is to characterize how psilocybin affects visual perception and the brain's representation of the visual environment. It is known that psilocybin alters aspects of visual perception, but the underlying brain mechanisms contributing to these effects are poorly ...
What is the current status of trial NCT05265546?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-03-08. Estimated completion is 2025-12-31.
What conditions does trial NCT05265546 study?
This clinical trial studies the following conditions: Perception Disorders.
What interventions are being tested in trial NCT05265546?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05265546?
This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05265546 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05265546's enrollment target sits among peer trials
80 672nd of 2000 higher than 1,305 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI